{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T10:38:17Z","timestamp":1789814297506,"version":"4.0.1"},"reference-count":32,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"unspecified","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"AlfaSigma S.p.A."},{"name":"PPP","award":["NSP-21-1-501"],"award-info":[{"award-number":["NSP-21-1-501"]}]},{"name":"Autoimmune Research and Collaboration Hub"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,1,11]]},"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Research into novel therapies for rare, immune-mediated inflammatory diseases (IMIDs) faces significant challenges, including small patient populations, complex clinical trial design and difficulties in patient recruitment. Patients with Beh\u00e7et\u2019s disease (BD), idiopathic inflammatory myopathies (IIM) and IgG4-related disease (IgG4-RD) typically undergo treatment involving prolonged administration of high-dose glucocorticoids and immunosuppressants. Both are associated with an increased risk of infection. Additionally, glucocorticoids carry long-term toxicity risks. Thus, there is an urgent need to develop more targeted and effective anti-inflammatory treatments. Given the activation of the type 1 interferon pathway in BD, IIM and IgG4-RD, inhibition of the Janus kinase (JAK) STAT pathway emerges as a promising therapeutic strategy. The Drug Rediscovery in IMIDs (DRIMID) consortium aims to conduct a prospective pilot basket trial to investigate the effects of filgotinib, a JAK1 preferential inhibitor approved for ulcerative colitis and rheumatoid arthritis, on disease activity, quality of life and safety in patients with refractory BD, IIM and IgG4-RD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>In this investigator-initiated, multicentre, open-label phase 2 study, up to 60 patients with rare IMIDs will be enrolled for a 26-week treatment period with filgotinib 200\u2009mg once daily. The trial consists of two stages, each involving a consecutively treated cohort of up to 20 patients per disease. An interim analysis is conducted between these stages, where the trial will proceed only in diseases showing potential effectiveness. Baseline, 3-month and 6-month assessments will include data on quality of life, disease activity, corticosteroid toxicity and biomarkers. The coprimary endpoints are disease activity and quality of life across and within each disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The study received approval from the Medical Research Ethics Committee in Utrecht, Netherlands. A Data Safety Monitoring Board has been established to monitor the trial\u2019s safety and progress.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT06285539\">NCT06285539<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-089827","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T05:31:08Z","timestamp":1738819868000},"page":"e089827","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Multicentre, 26-week, open-label phase 2 trial of the JAK inhibitor filgotinib in Beh\u00e7et\u2019s disease, idiopathic inflammatory myopathies and IgG4-related disease: DRIMID study protocol"],"prefix":"10.1136","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct06285539","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-4508-1812","authenticated-orcid":false,"given":"Bettina C","family":"Geertsema-Hoeve","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, University Medical Centre Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan A M","family":"van Laar","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Immunology, Erasmus MC, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost","family":"Raaphorst","sequence":"additional","affiliation":[{"name":"Department of Neurology and Clinical Neurophysiology, University of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sander W","family":"Tas","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centres, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paco M J","family":"Welsing","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, University Medical Centre Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robbert J","family":"Goekoop","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Rheumatology, HagaZiekenhuis, Den Haag, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar Magro","family":"Checa","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Zuyderland Medical Centre, Heerlen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rogier M","family":"Thurlings","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Radboudumc, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolle H","family":"Rekers","sequence":"additional","affiliation":[{"name":"Alfasigma S.p.A, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Present","sequence":"additional","affiliation":[{"name":"Alfasigma S.p.A, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob M","family":"van Laar","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, University Medical Centre Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,2,6]]},"reference":[{"key":"2025121220301464000_15.2.e089827.1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41572-021-00301-1","article-title":"Beh\u00e7et syndrome","volume":"7","author":"Yazici","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"2025121220301464000_15.2.e089827.2","first-page":"e1193","article-title":"Identification of distinctive interferon gene signatures in different types of myositis","volume":"93","author":"Pinal-Fernandez","year":"2019","journal-title":"Neurology (ECronicon)"},{"key":"2025121220301464000_15.2.e089827.3","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-012513-104708"},{"key":"2025121220301464000_15.2.e089827.4","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00665","article-title":"Immunopathogenesis of Behcet\u2019s Disease","volume":"10","author":"Tong","year":"2019","journal-title":"Front Immunol"},{"key":"2025121220301464000_15.2.e089827.5","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","article-title":"Idiopathic inflammatory myopathies","volume":"7","author":"Lundberg","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"2025121220301464000_15.2.e089827.6","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2021.1902310"},{"key":"2025121220301464000_15.2.e089827.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199910213411707"},{"key":"2025121220301464000_15.2.e089827.8","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/B978-0-7020-4086-3.00032-1","article-title":"Idiopathic inflammatory myopathies","volume":"119","author":"van der Kooi","year":"2014","journal-title":"Handb Clin Neurol"},{"key":"2025121220301464000_15.2.e089827.9","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.180353"},{"key":"2025121220301464000_15.2.e089827.10","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2020.1859710"},{"key":"2025121220301464000_15.2.e089827.11","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e3283418057"},{"key":"2025121220301464000_15.2.e089827.12","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1002\/art.39132","article-title":"International Consensus Guidance Statement on the Management and Treatment of IgG4-Related Disease","volume":"67","author":"Khosroshahi","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2025121220301464000_15.2.e089827.13","article-title":"Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis","volume":"2012","author":"Gordon","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"2025121220301464000_15.2.e089827.14","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1007\/s00415-014-7313-z","article-title":"Long-term follow-up of 62 patients with myositis","volume":"261","author":"van de Vlekkert","year":"2014","journal-title":"J Neurol"},{"key":"2025121220301464000_15.2.e089827.15","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2018.42"},{"key":"2025121220301464000_15.2.e089827.16","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.717388","article-title":"Emerging Place of JAK Inhibitors in the Treatment of Inborn Errors of Immunity","volume":"12","author":"Hadjadj","year":"2021","journal-title":"Front Immunol"},{"key":"2025121220301464000_15.2.e089827.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106210"},{"key":"2025121220301464000_15.2.e089827.18","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1201348"},{"key":"2025121220301464000_15.2.e089827.19","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s40744-019-00192-5","article-title":"Filgotinib, a JAK1 Inhibitor, Modulates Disease-Related Biomarkers in Rheumatoid Arthritis: Results from Two Randomized, Controlled Phase 2b Trials","volume":"7","author":"Tarrant","year":"2020","journal-title":"Rheumatol Ther"},{"key":"2025121220301464000_15.2.e089827.20","unstructured":"European Medicines Agency . EMA recommends measures to minimise risk of serious side effects with janus kinase inhibitors for chronic inflammatory disorders. 2022. Available: https:\/\/www.ema.europa.eu\/en\/news\/ema-recommends-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic-inflammatory-disorders"},{"key":"2025121220301464000_15.2.e089827.21","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90015-9"},{"key":"2025121220301464000_15.2.e089827.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816594"},{"key":"2025121220301464000_15.2.e089827.23","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-009-0191-z"},{"key":"2025121220301464000_15.2.e089827.24","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211400"},{"key":"2025121220301464000_15.2.e089827.25","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/bjd.18223","article-title":"Evaluating important change in cutaneous disease activity as an efficacy measure for clinical trials in dermatomyositis","volume":"182","author":"Ahmed","year":"2020","journal-title":"Br J Dermatol"},{"key":"2025121220301464000_15.2.e089827.26","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1002\/acr.23543","article-title":"An International Multispecialty Validation Study of the IgG4-Related Disease Responder Index","volume":"70","author":"Wallace","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025121220301464000_15.2.e089827.27","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.clnu.2022.03.019","article-title":"Immunomodulatory and clinical responses to zinc gluconate supplementation in patients with Beh\u00e7et\u2019s disease: A double-blind, randomized placebo-controlled clinical trial","volume":"41","author":"Faghfouri","year":"2022","journal-title":"Clin Nutr"},{"key":"2025121220301464000_15.2.e089827.28","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003268","article-title":"Phase 3, multicentre, randomised, double-blind, placebo-controlled, parallel-group study of ustekinumab in Japanese patients with active polymyositis and dermatomyositis who have not adequately responded to one or more standard-of-care treatments","volume":"9","author":"Kawahata","year":"2023","journal-title":"RMD Open"},{"key":"2025121220301464000_15.2.e089827.29","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/mus.24681","article-title":"Efficacy and safety of creatine supplementation in juvenile dermatomyositis: A randomized, double-blind, placebo-controlled crossover trial","volume":"53","author":"Solis","year":"2016","journal-title":"Muscle Nerve"},{"key":"2025121220301464000_15.2.e089827.30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408684"},{"key":"2025121220301464000_15.2.e089827.31","first-page":"1987","article-title":"Filgotinib: First Approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs (Abingdon Engl)"},{"key":"2025121220301464000_15.2.e089827.32","unstructured":"European Medicines Agency . Jyseleca. 2023. Available: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/jyseleca"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-089827","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T04:30:26Z","timestamp":1765600226000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-089827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":32,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2,6]]},"published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1136\/bmjopen-2024-089827"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-089827","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2]]}}}